Joslin Diabetes Center’s Office of Commercialization and Ventures is pharma partnering with Eli Lilly and Company and Pfizer which will enable Joslin and both companies to accelerate research aimed at predicting kidney failure in patients with type 2 diabetes and developing potential ways to treat and prevent this complication of diabetes.
This is the first time two pharmaceutical companies have joined forces with Joslin, the world’s leading diabetes research and clinical care organization, to identify biomarkers for predicting kidney disease.
As part of this co-funded pharma partnering research effort, Joslin will analyze samples from a unique biorepository collected and studied by Dr. Krolewski over a period of 15 years from Joslin type 2 diabetes patients in order to study specific biomarkers associated with the development of kidney failure, with the goal of predicting which patients are at risk of losing kidney function and eventually helping develop targeted drugs to address this condition.
Daily news stories
For further deal information visit Current Agreements (subscription required)
Report: Partnering Deals and Alliances with Eli Lilly
Report: Partnering deals and Alliances with Pfizer
View:Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity
Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now